Show simple item record

dc.contributor.authorRescigno, P
dc.contributor.authorDolling, D
dc.contributor.authorConteduca, V
dc.contributor.authorRediti, M
dc.contributor.authorBianchini, D
dc.contributor.authorLolli, C
dc.contributor.authorOng, M
dc.contributor.authorLi, H
dc.contributor.authorOmlin, AG
dc.contributor.authorSchmid, S
dc.contributor.authorCaffo, O
dc.contributor.authorZivi, A
dc.contributor.authorPezaro, CJ
dc.contributor.authorMorley, C
dc.contributor.authorOlmos, D
dc.contributor.authorRomero-Laorden, N
dc.contributor.authorCastro, E
dc.contributor.authorSaez, MI
dc.contributor.authorMehra, N
dc.contributor.authorSmeenk, S
dc.contributor.authorSideris, S
dc.contributor.authorGil, T
dc.contributor.authorBanks, P
dc.contributor.authorSandhu, SK
dc.contributor.authorSternberg, CN
dc.contributor.authorDe Giorgi, U
dc.contributor.authorDe Bono, JS
dc.date.accessioned2020-06-03T09:18:35Z
dc.date.issued2020-04
dc.identifier.citationEuropean urology oncology, 2020, 3 (2), pp. 176 - 182
dc.identifier.issn2588-9311
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3673
dc.identifier.eissn2588-9311en_US
dc.identifier.doi10.1016/j.euo.2019.06.008en_US
dc.description.abstractBackground Declines in prostate-specific antigen (PSA) levels at 12wk are used to evaluate treatment response in metastatic castration-resistant prostate cancer (mCRPC). PSA fall by ≥30% at 4wk (PSA4w30) has been reported to be associated with better outcome in a single-centre cohort study.Objective To evaluate clinical relevance of early PSA decline in mCRPC patients treated with next-generation hormonal treatments (NGHTs) such as abiraterone and enzalutamide.Design, setting, and participants This was a retrospective multicentre analysis. Eligible patients received NGHT for mCRPC between 6 January 2006 and 31 December 2017 in 13 cancer centres worldwide, and had PSA levels assessed at baseline and at 4 and/or 12wk after treatment. PSA response was defined as a ≥30% decline (progression as a ≥25% increase) from baseline.Outcome measurements and statistical analysis Association with overall survival (OS) was analysed using landmark multivariable Cox regression adjusting for previous chemotherapy, including cancer centre as a shared frailty term.Results and limitations We identified 1358 mCRPC patients treated with first-line NGHT (1133 had PSA available at 4wk, and 948 at both 4 and 12wk). Overall, 583 (52%) had a PSA4w30; it was associated with longer OS (median: 23; 95% confidence interval [CI]: 21-25) compared with no change (median: 17; 95% CI: 15-18) and progression (median: 13; 95% CI: 10-15). A PSA12w30 was associated with lower mortality (median OS 22 vs 14; hazard ratio=0.57; 95% CI=0.48-0.67; p<0.001). PSA4w30 strongly correlated with PSA12w30 (ρ=0.91; 95% CI=0.90-0.92; p<0.001). In total, 432/494 (87%) with a PSA4w30 achieved a PSA12w30. Overall, 11/152 (7%) patients progressing at 4wk had a PSA12w30 (1% of the overall population).Conclusions PSA changes in the first 4wk of NGHT therapies are strongly associated with clinical outcome from mCRPC and can help guide early treatment switch decisions.Patient summary Prostate-specific antigen changes at 4wk after abiraterone/enzalutamide treatment are important to determine patients' outcome and should be taken into consideration in clinical practice.
dc.formatPrint-Electronic
dc.format.extent176 - 182
dc.languageeng
dc.language.isoeng
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectHumans
dc.subjectPhenylthiohydantoin
dc.subjectAndrostenes
dc.subjectProstate-Specific Antigen
dc.subjectTreatment Outcome
dc.subjectSurvival Analysis
dc.subjectRetrospective Studies
dc.subjectTime Factors
dc.subjectMale
dc.subjectProstatic Neoplasms, Castration-Resistant
dc.titleEarly Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis.
dc.typeJournal Article
dcterms.dateAccepted2019-06-12
rioxxterms.versionofrecord10.1016/j.euo.2019.06.008
rioxxterms.licenseref.startdate2020-04en_US
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfEuropean urology oncology
pubs.issue2
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Prostate Cancer Targeted Therapy Group
pubs.publication-statusPublished
pubs.volume3en_US
pubs.embargo.termsNot known
icr.researchteamProstate Cancer Targeted Therapy Groupen_US
dc.contributor.icrauthorRescigno, Pasqualeen
dc.contributor.icrauthorDe Bono, Johannen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/